NCT00321802View on ClinicalTrials.gov

Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 30, 2006

Primary Completion Date

December 31, 2012

Study Completion Date

December 31, 2012

Conditions
Atrial Fibrillation
Interventions
DRUG

Simvastatin

Patients take 40 mg of simvastatin per day for 6 months.

DRUG

Placebo

Placebo

Trial Locations (1)

T2N 4N1

University of Calgary, Foothills Hospital, Calgary

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

lead

University of Calgary

OTHER

NCT00321802 - Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins | Biotech Hunter | Biotech Hunter